Clinical Trial

Safety Outcomes Post Kidney Biopsy - Randomized Clinical Evaluation of Efficacy of Desmopressin

Study acronym: STOP-BLEED
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
It is a randomized, multicenter, double-blind, placebo controlled, interventional clinical trial that will be conducted in Poland, in about 6 Hospital Nephrology Departments to evaluate the safety and effectiveness of desmopressin on the prevention of bleeding after percutaneous needle kidney biopsy in patients with rare and ultrarare glomerulonephritis.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-07-15; most recent amendment 2025-05-05.
Status change: Not Yet Recruiting → Recruiting 2022-11-21
Trial Details
NCT Number NCT05467033
Lead Sponsor Medical University of Bialystok
Conditions Kidney Biopsy
Enrollment 424 participants
Start Date 2022-09-01
Primary Completion 2026-08-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-08